SES/IMS
15.12.2021 08:52:11 CET | Business Wire | Press release
SES’s satellite-based trunking services will enable leading Colombian fibre optic networks service provider Integra Multisolutions (IMS) to extend and enhance fibre-like connectivity for Colombian municipalities with fewer than 100,000 inhabitants located out of the reach of terrestrial infrastructure, SES announced today. The new service will begin on SES’s O3b medium earth orbit (MEO) constellation and later migrate onto O3b mPOWER, SES’s next-generation MEO system, in 2022 when service will expand to additional cities.
The first site to be connected will be Puerto Leguizamo, a municipality located in the Putumayo Department in the southern border region of the country. SES and IMS will go on to deliver service to other sparsely populated cities across Colombia that experience poor or inconsistent connectivity services.
SES’s Trunk mPOWERED service will equip IMS to enable local Internet service providers to serve a combination of enterprise, residential, MNO and civilian government projects. IMS is among the first companies in Latin America to sign up for the O3b mPOWER system, which can deliver low-latency, high-speed, uncontended services from tens of megabits to multiple gigabits per second to a single site.
According to the Colombian Ministry of Telecommunications, fixed broadband subscriptions in the country reached 8.22 million in 2021, which translates to 16.10 subscriptions per 100 people. However, the National Administrative and Statistics Department (Dane) revealed earlier this year the results of the Survey of Information and Communication Technologies in Households (ENTIC Hogares) showing only 56.5% of the households surveyed have an internet connection. The survey identified an important difference between households in the main cities, where 66.6% have internet access, and those in rural and dispersed areas, where only 23.9% of the households do. The Putumayo Department is among the regions with challenges to access reliable connectivity services.
“By working together with SES, we are able to quickly and cost-effectively expand our network in underserved and tough-to-reach areas helping to address the digital divide for these communities,” said Juan Carlos Hernandez Mendoza, CEO of IMS Group. “Our goal is to provide our end users the best quality of service across Colombia, which means access to high-performing services at all times, no matter where they are. The capabilities of the proven O3b MEO fleet, and the scalability and flexibility of the upcoming O3b mPOWER services combined with SES satellite network and IMS fibre optics networks expertise, allow us to achieve exactly that.”
“Our multi-orbit satellite solutions have been bringing reliable connectivity services across Colombia for almost 10 years,” said Omar Trujillo, Americas Vice President of Fixed Data Sales at SES. “We are delighted to partner with IMS to extend terrestrial networks with the revolutionary capabilities of the O3b mPOWER constellation and deliver fibre-like Internet access to Colombians wherever they live.”
Follow us on:
Twitter
| Facebook
| YouTube
| LinkedIn
| Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,500 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About IMS
IMS was created in 2016, since then IMS is becoming the main PARTNER for all the small and medium Internet Service Providers in Colombia through terrestrial telecom technologies specialized in fiber optic networks, Networking Engineering, ISP Tech Solutions, supply chain, and many more. Currently IMS has more than 100,000 kilometres of available fiber throughout Colombia and sells more than 300 Gbps of fiber optic capacity to more than 250 corporate customers, becoming a very important provider for internet carriers in the region. For more information about IMS go to www.ims.net.co .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214006318/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom